RFP - supply of a CDK4/CDK6 inhibitor for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer
1 September 2019
PHARMAC invites proposals for the supply of a CDK4/CDK6 inhibitor for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer in New Zealand.
This request for proposals (RFP) document incorporates the following schedules:
- Schedule 1 specifies the pharmaceutical for which PHARMAC is requesting proposals and sets out the background to the RFP and the types of proposals sought;
- Schedule 2 describes the process that PHARMAC expects to follow in relation to the RFP;
- Schedule 3 sets out information about the estimated size of the current subsidised market for the pharmaceutical; and
- Schedule 4 contains the RFP form in which you are to provide details of your proposal [DOCX, 19 KB].
If you wish to submit a proposal, you must submit it to PHARMAC via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz(external link)) no later than 5pm NZT Monday 14 October 2019 - RFx ID 21504218.
We encourage suppliers to register with GETS and subscribe to this RFP. If you have any questions about this RFP, please post these on GETS (www.gets.govt.nz(external link)).
We look forward to receiving your proposal.
Last updated: 1 September 2019